Downgrades Archives - Page 258 of 277

1 minute read

Why This DocuSign Analyst Says There’s Downside Ahead

July 21, 12:35 PM

DocuSign Inc (NASDAQ: DOCU) has an elevated risk profile given the CEO transition, execution challenges, high employee turnover and a deteriorating macro environment, according to Piper Sandler.

ADBE

1 minute read

OTR Global Downgrades Papa John’s International to Mixed

By Benzinga Newsdesk

July 21, 12:12 PM

OTR Global downgrades Papa John's International (NASDAQ:PZZA) from Positive to Mixed.

PZZA

1 minute read

Deutsche Bank Downgrades Stryker to Hold, Lowers Price Target to $205

By Benzinga Newsdesk

July 21, 8:16 AM

Deutsche Bank analyst Pito Chickering downgrades Stryker (NYSE:SYK) from Buy to Hold and lowers the price target from $285 to $205.

SYK

1 minute read

Mizuho Downgrades Phillips Edison to Neutral, Announces $35 Price Target

By Benzinga Newsdesk

July 21, 7:14 AM

Mizuho analyst Haendel St. Juste downgrades Phillips Edison (NASDAQ:PECO) from Buy to Neutral and announces $35 price target.

PECO

1 minute read

William Blair Downgrades Shift Technologies to Market Perform

By Benzinga Newsdesk

July 21, 7:12 AM

William Blair analyst Sharon Zackfia downgrades Shift Technologies (NASDAQ:SFT) from Outperform to Market Perform.

SFT

1 minute read

Raymond James Downgrades Invitae to Market Perform

By Benzinga Newsdesk

July 21, 6:14 AM

Raymond James analyst Andrew Cooper downgrades Invitae (NYSE:NVTA) from Outperform to Market Perform.

NVTA

1 minute read

Chardan Capital Downgrades Vascular Biogenics to Neutral

By Benzinga Newsdesk

July 21, 5:56 AM

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

VBLT

1 minute read

Goldman Sachs Downgrades FIGS to Sell, Lowers Price Target to $7

By Benzinga Newsdesk

July 21, 5:54 AM

Goldman Sachs analyst Brooke Roach downgrades FIGS (NYSE:FIGS) from Neutral to Sell and lowers the price target from $14 to $7.

FIGS

1 minute read

Goldman Sachs Downgrades Henry Schein to Neutral, Lowers Price Target to $85

By Benzinga Newsdesk

July 21, 5:52 AM

Goldman Sachs analyst Nathan Rich downgrades Henry Schein (NASDAQ:HSIC) from Buy to Neutral and lowers the price target from $93 to $85.

HSIC

1 minute read

Morgan Stanley Downgrades Compass to Equal-Weight, Lowers Price Target to $5

By Benzinga Newsdesk

July 21, 5:49 AM

Morgan Stanley analyst Brian Nowak downgrades Compass (NYSE:COMP) from Overweight to Equal-Weight and lowers the price target from $7 to $5.

COMP